Time spent at blood pressure target and the risk of death and cardiovascular diseases
Open accessThe DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The time a patient spends with blood pressure at target level is an intuitive measure of successful BP management, but population studies on its effectiveness are as yet unavailable. METHOD: We identified a population-based cohort of 169,082 individuals with newly identified high blood pressure who were free of cardiovascular disease from January 1997 to March 2010. We used 1.64 million clinical blood pressure readings to calculate the TIme at TaRgEt (TITRE) based on current target blood pressure levels. RESULT: The median (Inter-quartile range) TITRE among all patients was 2.8 (0.3, 5.6) months per year, only 1077 (0.6%) patients had a TITRE ≥11 months. Compared to people with a 0% TITRE, patients with a TITRE of 3-5.9 months, and 6-8.9 months had 75% and 78% lower odds of the composite of cardiovascular death, myocardial infarction and stroke (adjusted odds ratios, 0.25 (95% confidence interval: 0.21, 0.31) and 0.22 (0.17, 0.27), respectively). These associations were consistent for heart failure and any cardiovascular disease and death (comparing a 3-5.9 month to 0% TITRE, 63% and 60% lower in odds, respectively), among people who did or did not have blood pressure 'controlled' on a single occasion during the first year of follow-up, and across groups defined by number of follow-up BP measure categories. CONCLUSION: Based on the current frequency of measurement of blood pressure this study suggests that few newly hypertensive patients sustained a complete, year-round on target blood pressure over time. The inverse associations between a higher TITRE and lower risk of incident cardiovascular diseases were independent of widely-used blood pressure 'control' indicators. Randomized trials are required to evaluate interventions to increase a person's time spent at blood pressure target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Individuals who remained at target BP levels for a higher proportion of time seemed to have a lower risk of incident cardiovascular diseases, which was independent of the widely used office BP ‘control’ indicators29.”
From Blood pressure and its variability: classic and novel measurement techniques (2022) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Chow, C. K. (2013) · JAMA · doi:10.1001/jama.2013.184182 · Cited by 1,991
Cited by
Banerjee, A., Pasea, L., Harris, S., Gonzalez-Izquierdo, A., Torralbo, A., Shallcross, L., Noursadeghi, M., Pillay, D., Sebire, N., Holmes, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30854-0 · Cited by 518
Self-citationBlood pressure and its variability: classic and novel measurement techniques
Schutte, A. E., Kollias, A., & Stergiou, G. S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00690-0 · Cited by 335
Bhatt, D. L., Vaduganathan, M., Kandzari, D. E., Leon, M. B., Rocha-Singh, K., Townsend, R. R., Katzen, B. T., Oparil, S., Brar, S., DeBruin, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01787-1 · Cited by 182
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 197
Mahfoud, F., Mancia, G., Schmieder, R. E., Ruilope, L. M., Narkiewicz, K., Schlaich, M. P., Williams, B., Ribichini, F. L., Weil, J., Kao, H., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.802 · Cited by 96
Self-citationSystolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events
Buckley, L. F., Baker, W. L., Tassell, B. W. V., Cohen, J. B., Alkhezi, O. S., Bress, A. P., & Dixon, D. L. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.20141 · Cited by 67
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes
Wang, N., Harris, K., Hamet, P., Harrap, S. B., Mancia, G., Poulter, N. R., Williams, B., Zoungas, S., Woodward, M., Chalmers, J. P., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.039 · Cited by 63
Self-citationMauer, N. S., Geldsetzer, P., Manne‐Goehler, J., Davies, J. I., Stokes, A., McConnell, M. A., Ali, M. K., Winkler, V. F., & Sudharsanan, N. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9522 · Cited by 43
“6% of people were able to sustain a year-round controlled BP in the first year of followup (27).”
BackgroundPrognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure
Chen, K., Li, C., Cornelius, V. R., Yu, D., Wang, Q., Shi, R., Wu, Z., Su, H., Yan, J., Chen, T., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.01.010 · Cited by 42
Time in Target Range for Blood Pressure and Adverse Health Outcomes: A Systematic Review
Wang, H., Song, J., Liu, Z., Yu, H., Wang, K., Qin, X., & Wu, Y. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24013 · Cited by 34
“Due to different TTR definitions, the results of 4 studies (Chung et al 22 , Mahfoud et al 25 , Chen KY et al 27 , and Cheng et al 29 ) were not included in the meta-analyses (Table S6).”
Gnanenthiran, S. R., Wang, N., Tanna, G. L. D., Salam, A., Webster, R. J., de Silva, H. A., Guggilla, R. K., Jan, S., Maulik, P. K., Naik, N., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0471 · Cited by 22
Darricarrère, C., Jacquot, E., Bricout, S., Louis, C., Bénard, M., & Poulter, N. R. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14699 · Cited by 20
Gnanenthiran, S. R., Tan, I., Atkins, E., Avolio, A. P., Bennett, B., Chapman, N., Chow, C. K., Freed, R., Gnjidic, D., Hespe, C. M., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.07.005 · Cited by 14
Blood pressure time at target and its prognostic value for cardiovascular outcomes: a scoping review
Li, W., Gnanenthiran, S. R., Schutte, A. E., & Tan, I. (2024) · Hypertension Research · doi:10.1038/s41440-024-01798-1 · Cited by 15
“Chung et al. similarly found an inverse association between TITRE and risk of incident cardio-vascular diseases [8].”
BackgroundMethodResultInfluentialChen, K., Wu, Z., Shi, R., Wang, Q., Yuan, X., Wu, G., Shi, G., Li, C., & Chen, T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110600 · Cited by 14
Feng, Z., Li, Y., Wang, C., Tian, L., Yao, S., Wang, M., Zhao, M., Lan, L., Wu, S., & Xue, H. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14816 · Cited by 13
Blood Pressure Time in Target Range and its Impact on Clinical Outcomes
Al-Dalakta, A., Tabaja, C., Motairek, I. K., Hajjar, A. H. E., Agarwal, N., John, J. S., & Laffin, L. J. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02111-9 · Cited by 16
“The RLI method offers a practical and broadly recognized means to evaluate the efficacy of BP management over time [12, 14–16].”
BackgroundMethodInfluentialCuffless blood pressure devices: the gap between patient acceptability and need for validation
Gnanenthiran, S. R., Liu, H., Tan, I., Chan, J., Schlaich, M. P., & Schutte, A. E. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003274 · Cited by 12
“Long-term BP readings are increasingly recognized to better relate to cardiovascular outcomes than cross-sectional readings [2].”
BackgroundDoes renal denervation require cardiovascular outcome-driven data?
Haider, S. A., Wagener, M., Iqbal, T., Shahzad, S., Sole, P. A. D., Leahy, N., Murphy, D., Sharif, R., Ullah, I., & Sharif, F. (2024) · Hypertension Research · doi:10.1038/s41440-024-01598-7 · Cited by 10
Malyutina, S. K., Викторовна, М. Е., Shapkina, M., Avdeeva, E. M., Maslatsov, N. A., Симонова, Г. И., Bobák, M., IuP, N., & Ryabikov, A. N. (2020) · Kardiologiia · doi:10.18087/cardio.2020.3.n948 · Cited by 10
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
The Trident Research Group (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2515043 · Cited by 12
Kim, M., Cho, M. S., Nam, G., Do, U., Kim, J., & Choi, K. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.06.036 · Cited by 9
Zhang, Y., Tian, X., Xu, Q., Xia, X., Chen, S., Wang, Y., Wu, S., & Wang, A. (2024) · Hypertension Research · doi:10.1038/s41440-024-01969-0 · Cited by 9
“Few studies have shown that a higher proportion of BP controlled within the target range was associated with a lower risk of CVD or mortality [9, 16].”
Schutte, A. E., & Gnanenthiran, S. R. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18156 · Cited by 7
Johnson, K., Beradid, S., Brophy, J. M., Platt, R. W., & Renoux, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-089834 · Cited by 5
Claessens, Z., Vanneste, A., Isterdael, C. V., Verbeke, C., Wens, I., & Huys, I. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03838-6 · Cited by 13
Johansson, J. S. M., Boström, K. B., Hjerpe, P., Mourtzinis, G., Kahan, T., & Ljungman, C. E. A. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.09.007 · Cited by 5
Baharudin, N., Ramli, A. S., Ramland, S. S., Badlie-Hisham, N. I., & Mohamed-Yassin, M.-S. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319231191017 · Cited by 7
Late outcomes of renal denervation are more favourable than early ones: facts or fancies?
Persu, A., Stoenoiu, M. S., Maes, F., Kreutz, R. H., Mancia, G., & Kjeldsen, S. E. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad231 · Cited by 6
“…a decreased incidence of all-cause mortality in a large cohort of veterans [ 20 ], a lower risk of all cardiovascular outcomes in a population-based cohort of subjects with newly identified high BP [ 21 ] and finally a decreased risk of a first major cardiovascular event in the SPRINT study [ 22 ].”
BackgroundBrewster, L. M., Boermeester, A. S., Seedat, Y. K., & van Montfrans, G. A. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003074 · Cited by 8
“Implications for practice Time spent at blood pressure target decreases risk of premature death [59], but blood pressure control is low globally, despite availability of antihypertensive drugs [5].”
BackgroundFisher, N. D. L., de Almeida, T. P., Perruchoud, D., Shah, J., & Solà, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1396962 · Cited by 4
Update on advanced interventional neuromodulatory approaches to lower blood pressure
Kiuchi, M. G., Carnagarin, R., Schultz, C. J., Shetty, S. V., Ward, N. C., Santos, C. E. R., & Schlaich, M. P. (2023) · Heart · doi:10.1136/heartjnl-2022-321499 · Cited by 3
Systolic Blood Pressure and Survival to Very Old Age: Results From the Women’s Health Initiative
Haring, B., Andrews, C., Hovey, K. M., Shadyab, A. H., LaCroix, A. Z., Martin, L. W., Rosal, M. C., Kuller, L. H., Salmoirago‐Blotcher, E., Saquib, N., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067302 · Cited by 5
“18,19,38,39 Our results on time in SBP target range in relation to survival probability emphasize 2 other key aspects of BP control.”
BackgroundВасильевич, И. М., Usova, E., Egorov, M. P., Звартау, Н. Э., & Конради, А. О. (2022) · Connected Health · doi:10.20517/ch.2022.12 · Cited by 5
Wang, H., Zhang, Y., Lin, J., Shu, Y., Bu, P., Wang, Z., Song, W., Zhang, Y., Yu, W., & Sun, N. (2025) · Blood Pressure · doi:10.1080/08037051.2025.2510317 · Cited by 3
Zhao, X., Liu, T., Yang, Q., Yang, G., Li, X., Tang, X., Li, J., Liang, Z., Li, A., Zeng, L., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03892-8 · Cited by 5
“Recent years, higher TTR was found associated with a decreased risk of death from any cause and major adverse cardio-vascular events [37–39].”
Time in Target Blood Pressure Range and Dementia
Glodzik, L., & Tzourio, C. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21413 · Cited by 2
Time in Target Range, All-Cause Mortality, and Cardiovascular Diseases
Wu, Z., Huo, Z., Huang, Z., Zhao, X., Wang, G., Ruan, C., Chen, S., & Wu, S. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpae144 · Cited by 1
AWARENESS, TREATMENT AND CONTROL OF ARTERIAL HYPERTENSION IN THE POPULATION (LITERATURE REVIEW)
Викторовна, М. Е., Аскетовна, А. Б., Ryabikov, A. N., & Malyutina, S. K. (2024) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2024-13-4s-168-182 · Cited by 1
Yang, Y., Wu, S.-L., Zhang, J., Liu, Y., Yin, M., Huo, Z., Chen, S., Wang, G., Xiao, Y., Wang, Y., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1537343 · Cited by 1
Ernst, M. E., Webb, K. L., Shah, R. C., Beilin, L. J., owen, A., Orchard, S. G., Fravel, M. A., Woods, R. L., Nelson, M. R., Polkinghorne, K. R., et al. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag070 · Cited by 2
Mishchenko, L. A., Матова, Е. А., & Сербенюк, Е. И. (2020) · Кардиология в Беларуси · doi:10.34883/pi.2020.12.4.008 · Cited by 1
Start und Ziele der Blutdrucktherapie
Häusermann, M. (2020) · pharma-kritik · doi:10.37667/pk.2020.1111
Alnemer, K. (2025) · Medicina · doi:10.3390/medicina61040764
“In recent years, an increased time in target range (TTR) has been correlated with a reduced risk of mortality from all causes and significant adverse cardiovascular events [56–58].”
Ahmed, A., Motuma, A., Firdisa, D., & Tola, A. (2025) · Journal of Public Health Research · doi:10.1177/22799036251388591
“12,64 These lifestyle factors should be prioritized in clinical practice, with health-care providers emphasizing the importance of lifestyle modifications in conjunction with pharmacological interventions.”
Systolic Blood Pressure Time in Target Range and Cerebral Small Vessel DiseasePreprint
Ji, G., Bai, M., Shi, H., Yang, L., Zhu, X., Li, R. Q., Li, J., Lv, H., Zhao, P., Chen, S., et al. (2025) · medRxiv · doi:10.64898/2025.12.24.25342993
Association Between 24-Hour Systolic Blood Pressure Time in Target Range and Mortality
Lauder, L., Schwantke, I., de la Sierra, A., Vinyoles, E., Gorostidi, M., Segura, J., Williams, B., Staplin, N., Ruilope, L. M., Böhm, M., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.26112
Self-citationВасильевич, И. М., Emelyanov, I. V., Yudina, Y., Курапеев, Д. И., Звартау, Н. Э., & Конради, А. О. (2026) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2025-2563
Gupta, A. K., Ahmed, A., Bowles, R., Learoyd, A., Kirkpatrick, E., Gurung, N., Rathod, K. S., Ahluwalia, A., & Mathur, A. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100778
“Methods from published work based on linear interpolation [31,32], area under curve for time spent within target BP [33] and proportion of the distribution of BP reading will be considered for calculating TTR for SBP. Effect size for primary endpoints will be reported as difference in mean daytime…”
Zhuang, M., Peng, X., Song, Q., Bai, J., Yu, M., & Cai, J. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004118
“[14,17,18] Previous studies have demonstrated significant associations between TTR and various clinical adverse outcomes, [14] including composite major adverse cardiovascular events, [19] atrial fibrillation, [20] cognitive disorder, [21,22] kidney events, [12] heart failure, [11] and stroke.”
Cooper, T., Martin, G., Beckley, I., Gao, W., & Williams, B. (2026) · doi:10.2196/preprints.103490
Self-citation
Metadata
- Authors
- Chung, S.-C., Pujades-Rodriguez, M., Duyx, B., Denaxas, S. C., Pasea, L., Hingorani, A., Timmis, A., Williams, B., & Hemingway, H.
- Affiliations
- Health Data Research UK (GB)
- Maastricht University (NL)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Chung, Sheng-Chia
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-09-05
- Volume
- 13
- Issue
- 9
- Pages
- e0202359
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6124703
- OpenAlex
- W2890722022
- Cited by
- 51
- References
- 46
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 9 · 2023: 7 · 2022: 13 · 2021: 1 · 2020: 4
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/M015084/1)
- National Institute for Health Research
- NIHR University College London Hospitals / UCL Biomedical Research Centre.
- Wellcome Trust (MR/K006584/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- blood pressure control, hypertension, cardiovascular disease, cardiovascular mortality, myocardial infarction, stroke, heart failure, newly diagnosed hypertension, antihypertensive efficacy
- MeSH terms
- Adult, Aged, Antihypertensive Agents, Blood Pressure, Blood Pressure Determination, Cardiovascular Diseases, Female, Humans, Hypertension, Male, Middle Aged, Risk Factors, Time Factors, Cohort Studies, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.